DK0838223T3 - Cerebral palsy inhibitor - Google Patents

Cerebral palsy inhibitor

Info

Publication number
DK0838223T3
DK0838223T3 DK96919984T DK96919984T DK0838223T3 DK 0838223 T3 DK0838223 T3 DK 0838223T3 DK 96919984 T DK96919984 T DK 96919984T DK 96919984 T DK96919984 T DK 96919984T DK 0838223 T3 DK0838223 T3 DK 0838223T3
Authority
DK
Denmark
Prior art keywords
endothelin antagonist
treating
brain edemas
edemas
preventing
Prior art date
Application number
DK96919984T
Other languages
Danish (da)
Inventor
Mitsuyoshi Ninomiya
Yoshiyuki Matsuo
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of DK0838223T3 publication Critical patent/DK0838223T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a composition for treating or preventing brain edemas which comprises an endothelin antagonist as an active ingredient, for example, the compound of the following formula (I): <CHEM> or pharmaceutically acceptable salts or hydrates thereof, bosentan, cycloÄD-aspartyl-L-Ä3-(4-phenylpiperazin-1-ylcarbonyl)Ü-alanyl-L-aspar tyl-D-Ä2-(2thienyl)Üglycyl-L-leucyl-D-tryptophylÜdisodium or cyclo ÄD-Asp-L-Pro-D-Val-L-Leu-D-TrpÜ. Furthermore, the present invention provides a method for treating or preventing brain edemas, which comprises administering an effective amount of an endothelin antagonist and use of an endothelin antagonist in the manufacture of a medicament for treating or preventing brain edemas. An endothelin antagonist exhibits an inhibitory effect on all brain edemas regardless of the mechanism of onset and thus is highly useful in the treatment or prevention of brain edemas. <IMAGE>
DK96919984T 1995-06-02 1996-05-29 Cerebral palsy inhibitor DK0838223T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16006095 1995-06-02
PCT/JP1996/001438 WO1996038173A1 (en) 1995-06-02 1996-05-29 Brain edema inhibitor

Publications (1)

Publication Number Publication Date
DK0838223T3 true DK0838223T3 (en) 2003-11-17

Family

ID=15707042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919984T DK0838223T3 (en) 1995-06-02 1996-05-29 Cerebral palsy inhibitor

Country Status (16)

Country Link
US (1) US5945448A (en)
EP (1) EP0838223B1 (en)
JP (1) JP4011114B2 (en)
KR (1) KR100399797B1 (en)
CN (1) CN1083261C (en)
AT (1) ATE245447T1 (en)
AU (1) AU700182B2 (en)
BR (1) BR9608413A (en)
CA (1) CA2218028C (en)
DE (1) DE69629195T2 (en)
DK (1) DK0838223T3 (en)
ES (1) ES2202449T3 (en)
PT (1) PT838223E (en)
TR (1) TR199701497T1 (en)
TW (1) TW460286B (en)
WO (1) WO1996038173A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482857B1 (en) 1998-07-17 2002-11-19 The University Of Texas Southwestern Medical Center Compositions which contain triterpenes for regulating hair growth
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
JP2007217438A (en) * 2001-07-17 2007-08-30 Shionogi & Co Ltd Medical preparation for injection
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US7861479B2 (en) 2005-01-14 2011-01-04 Airlite Plastics, Co. Insulated foam panel forms
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CA2793668A1 (en) 2011-10-31 2013-04-30 Bradley J. Crosby An apparatus and method for construction of structures utilizing insulated concrete forms
US8887465B2 (en) 2012-01-13 2014-11-18 Airlite Plastics Co. Apparatus and method for construction of structures utilizing insulated concrete forms
USD713975S1 (en) 2012-07-30 2014-09-23 Airlite Plastics Co. Insulative insert for insulated concrete form
US10787827B2 (en) 2016-11-14 2020-09-29 Airlite Plastics Co. Concrete form with removable sidewall
US11155995B2 (en) 2018-11-19 2021-10-26 Airlite Plastics Co. Concrete form with removable sidewall

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115665T3 (en) * 1991-01-29 1998-07-01 Shionogi & Co DERIVED FROM TRITERPEN.
EP0682009B1 (en) * 1993-06-11 1998-05-06 Shionogi & Co., Ltd. Intermediate compounds for preparing endothelin-receptor antagonist triterpene derivatives
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists

Also Published As

Publication number Publication date
DE69629195D1 (en) 2003-08-28
PT838223E (en) 2003-12-31
EP0838223A4 (en) 2001-04-25
CA2218028C (en) 2010-07-06
KR100399797B1 (en) 2004-04-13
DE69629195T2 (en) 2004-05-06
ATE245447T1 (en) 2003-08-15
WO1996038173A1 (en) 1996-12-05
TW460286B (en) 2001-10-21
US5945448A (en) 1999-08-31
CN1186441A (en) 1998-07-01
AU5844096A (en) 1996-12-18
TR199701497T1 (en) 1998-06-22
EP0838223B1 (en) 2003-07-23
BR9608413A (en) 1998-12-29
CA2218028A1 (en) 1996-12-05
JP4011114B2 (en) 2007-11-21
AU700182B2 (en) 1998-12-24
KR19990008341A (en) 1999-01-25
EP0838223A1 (en) 1998-04-29
ES2202449T3 (en) 2004-04-01
CN1083261C (en) 2002-04-24
MX9708920A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
ATE195117T1 (en) 1-AMDINOPHENYL-PYRROLIDONE/PIPERIDINONE AS BLOOD ROLLET AGGREGATION INHIBITORS
DK0838223T3 (en) Cerebral palsy inhibitor
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE69413237T2 (en) PLATE AGGREGATION INHIBITORS
RU94036772A (en) Application of 2-phenyl-3-aroylbenzothiophenes for endometriosis inhibition
RU94044454A (en) Inhibitor of autoimmune diseases
BR0113389A (en) Compounds that inhibit factor xa activity
RU94044356A (en) Use of 2-phenyl-3-aroylbenzothiophenes for thrombodulin expression increase to inhibit thrombotic disorder, for protein c activation
ES2110115T3 (en) PLATELET AGGREGATION INHIBITORS.
DE60225143D1 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PROPHYLAXIS OF DIABETES
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner&#39;s syndrome inhibition
DK0804418T3 (en) Platelet aggregation inhibitors
DK0866711T3 (en) Use of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide for the preparation of a pharmaceutical composition for the prevention of sleep apnea
ATE160143T1 (en) 2-SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES AS GABA-B ANTAGONISTS
PL313037A1 (en) Phenoxphenylocyclopententenylohydroxyureas
ES2140531T3 (en) INTERLEUKIN-1 INHIBITOR.
AU2101792A (en) Methanoanthracene D2 dopamine antagonists
WO2024075070A3 (en) Novel bicyclic heterocyclyl compounds and use thereof